Related Experiment Videos
Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia
Insights
This study improved event-free survival in children with acute lymphoblastic leukemia (ALL) using intensive chemotherapy. The new treatment program showed better outcomes for both standard-risk and high-risk ALL patients.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Trials
Background:
- Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
- Risk stratification is crucial for tailoring ALL treatment protocols.
- Previous treatment regimens had variable success rates in pediatric ALL.
Purpose of the Study:
- To evaluate a novel treatment program for pediatric acute lymphoblastic leukemia.
- To compare event-free survival rates between standard-risk and high-risk ALL patients.
- To identify prognostic indicators within the high-risk ALL subgroup.
Main Methods:
- Prospective assignment of 289 children with ALL to standard-risk or high-risk treatment arms.
- High-risk factors included age, white-cell count, T-cell markers, mediastinal mass, and central nervous system involvement.
- Treatment involved intensive remission-induction, CNS prophylaxis, high-dose asparaginase, and multi-drug continuation therapy.
Main Results:
- Four-year event-free survival was 86% for standard-risk and 71% for high-risk ALL patients (overall 77%).
- The intensive asparaginase and four-drug induction therapy improved outcomes compared to previous methods.
- In high-risk patients, age under 12 months was a significant predictor of poor outcome.
Conclusions:
- The implemented treatment program significantly improved event-free survival in children with ALL.
- Risk stratification effectively identified patient subgroups requiring different therapeutic intensities.
- Early age at diagnosis remains a critical factor for poor prognosis in high-risk pediatric ALL.
Abstract:
We prospectively assigned 289 consecutive children with acute lymphoblastic leukemia to receive one of two treatment programs on the basis of the presence or absence of certain risk factors at the time of diagnosis. Patients at high risk (62 percent of the total) had one or more of the following risk factors: age below two or above nine years, a white-cell count of 20,000 per cubic millimeter or more, the presence of T-cell immunologic markers, radiologic evidence of a mediastinal mass, and involvement of the central nervous system. Patients in both the standard-risk and high-risk groups were treated for two years, receiving intensive remission-induction therapy, central nervous system prophylaxis, weekly administration of high-dose asparaginase, and multiple-drug continuation therapy (which in the high-risk group included doxorubicin and a larger dose of prednisone). At a median follow-up of 35 months, the mean (+/- SE) event-free survival rates at four years among the patients in the standard-risk and high-risk groups were 86 +/- 4 percent and 71 +/- 4 percent, respectively (P = 0.003), for a total event-free survival of 77 +/- 3 percent. Within the high-risk group, the white-cell count at diagnosis and the sex of the patient were not significant prognostic indicators, but age below 12 months at diagnosis was associated with a very poor outcome. As compared with previous methods, this treatment program using four-drug induction and intensive asparaginase therapy has resulted in improved event-free survival in children with acute lymphoblastic leukemia.